Recent Quotes (30 days)

You have no recent quotes
chg | %

Avid Bioservices Inc  

(Public, NASDAQ:CDMO)   Watch this stock  
Find more results for NASDAQ:PPHM
3.91
+0.10 (2.62%)
After Hours: 4.00 +0.09 (2.30%)
Jan. 16, 5:51p.m. EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.71 - 3.92
52 week 1.98 - 5.78
Open 3.85
Vol / Avg. 119,500.00/228,301.00
Mkt cap 176.78M
P/E     -
Div/yield     -
EPS -0.70
Shares 45.21M
Beta 2.73
Inst. own 21%
Jan. 18, 2018
Avid Bioservices Inc Annual Shareholders Meeting - 1:00p.m. EST - Add to calendar
Dec. 11, 2017
Q2 2018 Peregrine Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct. '17) 2017
Net profit margin -98.76% -48.86%
Operating margin -98.87% -49.04%
EBITD margin - -44.76%
Return on average assets -56.61% -24.79%
Return on average equity -114.08% -63.29%
Employees 319 -
CDP Score - -

Address

2642 Michelle Dr Ste 200
TUSTIN, CA 92780-7019
United States - Map
+1-714-5086100 (Phone)
+1-714-8385817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., incorporated on September 25, 1996, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides a variety of process development activities, including cell line development and optimization.

Officers and directors

Roger J. Lias Ph.D. President, Chief Executive Officer
Bio & Compensation  - Reuters
Paul J. Lytle Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark R. Ziebell Vice President, General Counsel, Corporate Secretary
Age: 52
Bio & Compensation  - Reuters
Shelley P.M. Fussey Ph.D. Vice President - Intellectual Property
Age: 50
Bio & Compensation  - Reuters
Joseph Carleone Ph.D. Director
Bio & Compensation  - Reuters
Richard B. Hancock Director
Bio & Compensation  - Reuters
Joel McComb Director
Bio & Compensation  - Reuters
Gregory P. Sargen Director
Bio & Compensation  - Reuters
Mark R. Bamforth Independent Director
Age: 52
Bio & Compensation  - Reuters